↓ Skip to main content

Treatment of Tourette Syndrome

Overview of attention for article published in Neurotherapeutics, January 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
126 Mendeley
Title
Treatment of Tourette Syndrome
Published in
Neurotherapeutics, January 2014
DOI 10.1007/s13311-013-0215-4
Pubmed ID
Authors

Roger M Kurlan

Abstract

Tourette's syndrome (TS) consists of chronic motor and phonic tics and characteristically begins in childhood. The tics can be disabling and commonly associated behavioral comorbities such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), can also cause problems in daily functioning. The underlying etiology and neurobiology of TS remain unknown although genetic factors appear to be important, cortical control of basal ganglia motor function appears to be disturbed and neurochemical abnormalities, particularly involving dopamine neurotransmission, are likely present. The treatment of TS involves appropriate education and support. Tics can be treated with habit reversal cognitive behavioral therapy, medications (most commonly alpha agonists and antipsychotics), local intramuscular injections of botulinum toxin and some severe, refractory cases have responded to deep brain stimulation surgery (DBS). It is important to appropriately diagnose and treat comorbid behavioral disorders that are disrupting function. OCD can be treated with cognitive behavioral therapy, selective serotonin reuptake inhibitors, and atypical antipsychotics. DBS has become a treatment option for patients with disabling OCD despite other therapies. ADHD is treated with appropriate classroom accommodations, behavioral therapy, alpha agonists, atomoxetine or methylphenidate-containing stimulant drugs.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Canada 1 <1%
Brazil 1 <1%
Unknown 123 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 25 20%
Researcher 14 11%
Student > Ph. D. Student 13 10%
Student > Master 12 10%
Professor > Associate Professor 11 9%
Other 25 20%
Unknown 26 21%
Readers by discipline Count As %
Medicine and Dentistry 30 24%
Psychology 20 16%
Agricultural and Biological Sciences 10 8%
Neuroscience 10 8%
Nursing and Health Professions 7 6%
Other 20 16%
Unknown 29 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2014.
All research outputs
#22,758,309
of 25,371,288 outputs
Outputs from Neurotherapeutics
#1,225
of 1,308 outputs
Outputs of similar age
#280,461
of 319,271 outputs
Outputs of similar age from Neurotherapeutics
#15
of 15 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,271 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.